We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.
BHVN

Delisted

BHVN was delisted on the 3rd of October, 2022.

Back to rankings

69 hedge funds and large institutions have $335M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2017 Q2 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
69
Holders Change
+69
Holders Change %
–
% of All Funds
1.72%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.1%
New
69
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$56.4M
2
VMI
VHCP Management II
New York
+$38.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.8M
4
BlackRock
BlackRock
New York
+$23.5M
5
KCM
Knoll Capital Management
Florida
+$18.6M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$2.15M +$1.98M +85,798 New
LCM
27
Laurion Capital Management
New York
$2.14M +$1.97M +85,625 New
GGHC
28
Gilder Gagnon Howe & Co
New York
$1.93M +$1.78M +77,169 New
EC
29
EcoR1 Capital
California
$1.75M +$1.61M +70,000 New
American Century Companies
30
American Century Companies
Missouri
$1.41M +$1.3M +56,390 New
EAM
31
Eventide Asset Management
Massachusetts
$1.33M +$1.23M +53,240 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.31M +$1.21M +52,357 New
Norges Bank
33
Norges Bank
Norway
$1.25M +$1.15M +50,000 New
MIM
34
Monashee Investment Management
Massachusetts
$1.24M +$1.14M +49,390 New
Charles Schwab
35
Charles Schwab
California
$909K +$837K +36,332 New
AA
36
ALPS Advisors
Colorado
$772K +$712K +30,897 New
FCMI
37
Foresite Capital Management III
California
$750K +$691K +30,000 New
Wells Fargo
38
Wells Fargo
California
$655K +$604K +26,213 New
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$475K +$437K +18,994 New
TA
40
Teachers Advisors
New York
$445K +$410K +17,789 New
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$443K +$408K +17,700 New
PAM
42
Panagora Asset Management
Massachusetts
$408K +$375K +16,300 New
RJA
43
Raymond James & Associates
Florida
$393K +$362K +15,710 New
Russell Investments Group
44
Russell Investments Group
United Kingdom
$388K +$358K +15,535 New
Two Sigma Investments
45
Two Sigma Investments
New York
$340K +$314K +13,618 New
Deutsche Bank
46
Deutsche Bank
Germany
$326K +$302K +13,131 New
Morgan Stanley
47
Morgan Stanley
New York
$289K +$266K +11,562 New
TRCT
48
Tower Research Capital (TRC)
New York
$275K +$253K +11,001 New
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$257K +$237K +10,272 New
MC
50
Matisse Capital
Oregon
$250K +$230K +10,000 New
1
2
3

BHVN Hedge Fund Activity: Q2 2017 in Review

69 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2017, worth a combined $335M.

Buyers outnumbered sellers: 69 funds opened new BHVN positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $56.4M.

  • 69 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2017, up from 0 in Q1 2017.
  • Funds reported $335M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2017.
  • 69 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2017 and 0 closed out, a net change of +69 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2017 was RA Capital Management, an estimated $56.4M added.

Based on aggregated 13F filings for Q2 2017.